Affordable Access

deepdyve-link
Publisher Website

The use of pharmacological preventive therapy for migraine with weight gain potential amid COVID‐19 pandemic

Authors
  • Kow, Chia Siang1
  • Hasan, Syed Shahzad2
  • 1 International Medical University, Malaysia , (Malaysia)
  • 2 University of Huddersfield, United Kingdom , (United Kingdom)
Type
Published Article
Journal
Headache The Journal of Head and Face Pain
Publisher
Wiley (Blackwell Publishing)
Publication Date
Aug 13, 2020
Identifiers
DOI: 10.1111/head.13945
PMID: 32790208
PMCID: PMC7436854
Source
PubMed Central
License
Unknown
External links

Abstract

We read with interest the narrative review by Arca et al. [1] on the use of headache medicines, specifically non‐steroidal anti‐inflammatory drugs (NSAIDs) and corticosteroids, amid novel coronavirus disease 2019 (COVID‐19) pandemic. Arca et al. [1] have comprehensively summarized current understanding of the risks and benefits of NSAIDs and corticosteroids to facilitate decision‐making by the clinicians. Nevertheless, we feel that headache medicines including the tricyclic antidepressant amitriptyline and the anticonvulsant valproate that possess the potential for weight gain are also worthy of discussion.

Report this publication

Statistics

Seen <100 times